Overview

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences